drugset / Trial / NCT05814393
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A multicenter, randomized, double-blind, placebo-controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2203
Timeline
- Start
- 2023-01-03
- Primary completion
- 2024-05-14
- Completion
- 2024-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JW0201 | Unknown | 200 mg | Oral |
| Background | C2022 | Unknown | 1000 mg | Oral |
| Background | C2203 | Unknown | 25 mg | Oral |